Stimulant, Sedative, Tobacco, Inhalant, Hallucinogen, and Caffeine-Related Disorders
Problematic use of each respective substance (e.g., amphetamines, benzodiazepines, LSD, nicotine, etc.) causing clinically significant impairment.
Etiology (Biopsychosocial Model)
Biological: Genetic vulnerability (family history of substance use disorders), neurochemical imbalances (dopamine, GABA, glutamate), altered brain reward pathways, and tolerance/withdrawal mechanisms.
Psychological: Personality traits (impulsivity, sensation-seeking), co-occurring mental health disorders (depression, anxiety), maladaptive coping strategies, and learned associations with substance use.
Social: Peer pressure, availability and accessibility of substances, cultural attitudes, family dysfunction, trauma, and socioeconomic stressors.
Symptoms & Diagnosis:
C - Craving
R - Role failures
A - Activities reduced
V - Very risky use
I - Interpersonal issues
N - No control
G - Great deal of time used
S - Social/psychological problems
S - Strong desire to stop
T - Tolerance
O - Overuse
P - Physical/psychological withdrawal
Treatment
Substance-specific behavioral therapy
Pharmacotherapy (e.g., nicotine patches, bupropion, modafinil for stimulants)
Harm reduction, detox, relapse prevention
Info
DSM-5-TR Code
Stimulant: F15.xx
Sedative/Hypnotic: F13.xx
Tobacco: F17.xx
Inhalant: F18.xx
Hallucinogen: F16.xx
Caffeine: F15.99 (unspecified)
Prevalence
NA